Health Condition 1: L40- Psoriasis
Conditions
Interventions
None listed
Sponsors
Central Council for Research in Homoeopathy
Eligibility
Inclusion criteria
Inclusion criteria: Cases presenting with plaque type psoriasis i.e., well-defined, erythematous, scaly lesion which becomes slivery on attempt to scrape.
Exclusion criteria
Exclusion criteria: 1.Cases with guttate psoriasis & pustular psoriasis. 2.Cases with psoriatic arthritis 3.Not on any treatment for psoriasis over the last 6 months 4.Patents willing to refrain from using any of the following treatments during the study period: o Systemic treatments for psoriasis (e.g., PUVA, cyclosporine, corticosteroids, methotrexate, oral retinoids, MMF, thioguanine, hydroxyurea, sirolimus, azathioprine, 6-MP, etanercept) and immunosuppressive medications for any indication other than psoriasis. o Treatment with UVB phototherapy and all other topical treatments for psoriasis (e.g., topical corticosteroids, calcipotriene, tazarotene, anthralin, tar). Tanning booths or non-prescription UV light sources are not to be used. •Evidence of skin conditions (eg, eczema) other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis •Be a candidate for systemic immune-suppressive therapy, in the opinion of the investigator, where in the patient has generalized psoriasis with significant functional impairment and high levels of distress.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in psoriasis severity, which is assessed by grading systems using PASI score. Psoriasis Area and Severity Index (PASI) is an established psoriasis severity assessment tool that will be used as a measure of the effects of homoeopathic treatment in patients of psoriasis at baseline and at monthly intervals for 12 months â?¢Change in participant quality of life score as measured by validated psoriasis specific quality of life scales i.e. Psoriasis Disability Index (PDI). Timepoint: Baseline at 0, monthly follow up at 1,2,3,4,5,6,7,8,9,10,11,12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to next ï¬?are measured during the period of follow upTimepoint: at monthly follow up 1,2,3,4,5,6,7,8,9,10,11,12 months | — |
Countries
India
Contacts
Public ContactDr Anil Khurana
Central Council for Research in Homoeopathy
Outcome results
None listed